UCB SA (OTCMKTS:UCBJF) Sees Significant Increase in Short Interest

UCB SA (OTCMKTS:UCBJF) was the target of a large increase in short interest in March. As of March 31st, there was short interest totalling 584,000 shares, an increase of 21.4% from the March 15th total of 481,000 shares. Based on an average trading volume of 700 shares, the short-interest ratio is presently 834.3 days. Approximately 0.3% of the shares of the company are short sold.

UCB Stock Performance

UCBJF stock opened at $150.70 on Tuesday. UCB has a 1-year low of $126.05 and a 1-year high of $209.66. The firm has a fifty day moving average price of $180.18 and a two-hundred day moving average price of $184.03. The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.